Bevacizumab’s Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgically Resected NSCLC

INTRODUCTION: ECOG-ACRIN E1505 was a phase 3 randomized trial of adjuvant chemotherapy with or without bevacizumab for patients with stages IB (>4 cm) to IIIA NSCLC. We sought to estimate the incidence and risk factors for brain recurrence as compared with extracranial recurrences (ECRs). METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Varlotto, John M., Wang, Yating, Sun, Zhuoxin, Wakelee, Heather A., Ramalingam, Suresh, Schiller, Joan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908250/
https://www.ncbi.nlm.nih.gov/pubmed/35281954
http://dx.doi.org/10.1016/j.jtocrr.2021.100274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908250/
https://www.ncbi.nlm.nih.gov/pubmed/35281954
http://dx.doi.org/10.1016/j.jtocrr.2021.100274

Ejemplares similares